201 related articles for article (PubMed ID: 11008016)
21. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli R; Bandini G; Testoni N; Amabile M; Ottaviani E; Buonamici S; Soverini S; Montefusco V; de Vivo A; Bonifazi F; Tura S; Cavo M
Haematologica; 2000 Sep; 85(9):930-4. PubMed ID: 10980631
[TBL] [Abstract][Full Text] [Related]
22. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
Nakao M; Janssen JW; Flohr T; Bartram CR
Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
[TBL] [Abstract][Full Text] [Related]
23. Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR.
Tögel F; Kröger N; Korioth F; Fehse B; Zander AR
J Hematother Stem Cell Res; 2002 Dec; 11(6):971-6. PubMed ID: 12590712
[TBL] [Abstract][Full Text] [Related]
24. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients.
Sedlarikova L; Kubiczkova L; Kryukov F; Pelcova J; Adam Z; Pour L; Hajek R; Sevcikova S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):554-61. PubMed ID: 24993743
[TBL] [Abstract][Full Text] [Related]
25. Quantitative assessment of contaminating tumor cells in autologous peripheral blood stem cells of B-cell non-Hodgkin lymphomas using immunoglobulin heavy chain gene allele-specific oligonucleotide real-time quantitative-polymerase chain reaction.
Yashima A; Maesawa C; Uchiyama M; Tarusawa M; Satoh T; Satoh M; Enomoto S; Sugawara K; Numaoka H; Murai K; Utsugisawa T; Ishida Y; Masuda T
Leuk Res; 2003 Oct; 27(10):925-34. PubMed ID: 12860013
[TBL] [Abstract][Full Text] [Related]
26. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
27. Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests.
Ladetto M; Omedè P; Sametti S; Donovan JW; Astolfi M; Drandi D; Volpato F; Giaccone L; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M
Exp Hematol; 2002 Jun; 30(6):529-36. PubMed ID: 12063019
[TBL] [Abstract][Full Text] [Related]
28. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
29. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
30. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
[TBL] [Abstract][Full Text] [Related]
31. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease.
Billadeau D; Blackstadt M; Greipp P; Kyle RA; Oken MM; Kay N; Van Ness B
Blood; 1991 Dec; 78(11):3021-9. PubMed ID: 1954387
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.
Silvennoinen R; Lundan T; Kairisto V; Pelliniemi TT; Putkonen M; Anttila P; Huotari V; Mäntymaa P; Siitonen S; Uotila L; Penttilä TL; Juvonen V; Selander T; Remes K
Blood Cancer J; 2014 Oct; 4(10):e250. PubMed ID: 25303369
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease monitoring in multiple myeloma.
Davies FE; Rawstron AC; Owen RG; Morgan GJ
Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
[TBL] [Abstract][Full Text] [Related]
34. Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma.
Bai Y; Chim CS
Hematology; 2019 Dec; 24(1):533-537. PubMed ID: 31280705
[TBL] [Abstract][Full Text] [Related]
35. [Real-time quantitative PCR detecting minimal residual disease in multiple myeloma patients after autologous peripheral blood stem cell transplantation].
Lin FY; Hou J; Tan LY; Ding SQ; Wang H; Wang DX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):516-20. PubMed ID: 14575549
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
37. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
[TBL] [Abstract][Full Text] [Related]
38. Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers.
Welterlin V; Debecker A; Tschieb D; Zanetti C; Lange W; Hénon PR
J Hematother Stem Cell Res; 2000 Dec; 9(6):983-91. PubMed ID: 11177613
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
[TBL] [Abstract][Full Text] [Related]
40. Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.
Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Díaz MG; San Miguel JF; García-Sanz R
Eur J Haematol; 2012 Oct; 89(4):328-35. PubMed ID: 22805350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
